Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program
NCT ID: NCT00401726
Last Updated: 2012-04-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
537 participants
INTERVENTIONAL
2006-06-30
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients
NCT00247429
A Study Of New Medicine (GSK 372475) For The Treatment Of Depression
NCT00448058
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
NCT01441440
Study Evaluating Venlafaxine ER in Recurrent Depression
NCT00046020
Treatments for Depression: Drug Versus Psychotherapy
NCT00043550
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Venlafaxine ER
Dialogues Time to Talk Program
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 18 years of age
Exclusion Criteria
* Current treatment with venlafaxine
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Birmingham, Alabama, United States
Mesa, Arizona, United States
Little Rock, Arkansas, United States
San Jose, California, United States
Avon, Connecticut, United States
Cromwell, Connecticut, United States
Wilmington, Delaware, United States
Ocala, Florida, United States
Pinellas Park, Florida, United States
Stuart, Florida, United States
Atlanta, Georgia, United States
Cartersville, Georgia, United States
Rome, Georgia, United States
Idaho Falls, Idaho, United States
Newburgh, Indiana, United States
Waterloo, Iowa, United States
Metairie, Louisiana, United States
Benzonia, Michigan, United States
Interlochen, Michigan, United States
Kalamazoo, Michigan, United States
Chesterfield, Missouri, United States
Omaha, Nebraska, United States
Las Vegas, Nevada, United States
Charlotte, North Carolina, United States
Charlotte, North Carolina, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Kettering, Ohio, United States
Mason, Ohio, United States
Mogadore, Ohio, United States
Allentown, Pennsylvania, United States
Newtown, Pennsylvania, United States
Reading, Pennsylvania, United States
Warwick, Rhode Island, United States
Anderson, South Carolina, United States
Greer, South Carolina, United States
Bristol, Tennessee, United States
Dallas, Texas, United States
Fort Worth, Texas, United States
Plano, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Charleston, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0600B1-416
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.